Dr Reddy's Lab partners with Alvotech to Co-Develop & commercialize Biosimilar Candidate

Hyderabad, June 5 (UNI) Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Hyderabad-based Dr. Reddy's Laboratories Ltd, on Thursday announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets.
Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancerTypes, Hyderabad based pharma giant said in a release here.
In 2024, worldwide sales of Keytruda were US$29.5 billion.
The collaboration combines Dr.Reddy's and Alvotech's proven capabilities in biosimilars, thereby speeding up the development process and extending the global reach for this biosimilar candidate.
Under the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally.
'We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R& D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patient's world-wide,' said Róbert Wessman, chairman and CEO of Alvotech.
Dr Reddy's CEO Erez Israeli said 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally, oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of themost critical therapies in immuno-oncology.'
UNI KNR BD

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Time of India

30 minutes ago

• Time of India

Cheated investor of 3.66 cr, scamster's Dubai run ends in extradition

Surat: A Surat-based property broker, Upvan Jain alias Bunty Jain, who fled to Dubai after allegedly cheating a 62-year-old private sector employee of Rs 3.66 crore in a property scam, was deported by the United Arab Emirates (UAE) authorities following an extradition request by the Indian govt. Jain was taken into custody by the Surat Police Economic Offences Cell at Ahmedabad airport on Saturday and was produced in court the following day. He was remanded to three days of police custody. The case against Jain and his eight accomplices was registered at Adajan police station and later transferred to the Economic Offences (Eco) Cell for further investigation. According to the police, Jain operated as a broker in Surat and allegedly duped Gyanchand Jain between 2019 and 2020 by promising high returns on real estate investments. He sold him four properties — an office in VIP Plaza and flats in River Palace, The Legend and Castle Brown residential complexes — and collected Rs 3.66 crore in the process. Investigations revealed that Jain and his associates created forged sale deeds, used stolen govt stamp papers and opened fake bank accounts to receive and divert the funds. These accounts were registered with Sutex Co-operative Bank, IndusInd Bank and Surat People's Co-operative Bank. The money was subsequently routed through multiple accounts to avoid detection. On learning about the fraud, Gyanchand filed a police complaint against nine people: Upvan Jain, Ashwin Langadiya, Arif Pathan, Naresh Vadhel, Rasik Ambaliya, Bansi Kalsariya, Sangita Kalsariya, Chetan Magroliya, and Vijay Langadiya. While the Eco Cell has already arrested the other eight accused, Jain had fled India. After the complaint was lodged, Upvan initially took shelter in his hometown Udaipur, Rajasthan, before flying to Dubai. A Lookout Circular (LOC) was issued against him, but with no return in sight, the Indian govt pursued extradition under its bilateral treaty with the UAE. Based on India's formal request, Interpol detained Jain in Dubai. He was deported to India after the legal process was completed and handed over to Surat police at Ahmedabad airport.

New Indian Express

an hour ago

• New Indian Express

‘We plan to add 1,700 beds by FY27; 57% beds likely in tier 2/3 cities'

Kochi- and Dubai-based Aster DM Healthcare, founded by Dr Azad Moopen in 1987 with a single clinic in Dubai, expects to complete the takeover of the Blackstone and TPG-backed Quality Care Hospital by the fourth quarter of this fiscal. The takeover will result in the third largest hospital chain Aster Quality Care, after Apollo and Fortis, with 38 hospitals across four brands -- Aster DM, Care Hospitals, KIMS Health and Evercare -- offering over 10,150 beds spread across 27 locations. Aster Quality Care is now jointly controlled by the Moopen family holding 24% and Blackstone owning 30.7%. In an interaction with Benn Kochuveedan of TNIE, Dr Azad Moopen shares his plans and expectations from the largest deal that his group has done. Excerpts: When do you see the merger of Quality Care Hospital getting completed? What are the targets in terms of revenue, profit expansion etc? The merger brings together four leading healthcare brands — Aster DM, Care Hospitals, KIMS Health, and Evercare — forming one of the largest hospital chains with 38 hospitals and over 10,150 beds across 27 cities. Financially, the merger strengthens the balance sheet and cash flow, enabling accelerated expansion plans. We aim to increase bed capacity to around 13,300 beds by FY27, further expanding our reach into tier 2 and 3 cities, providing a platform for sustained growth in the future. The merger is expected to be concluded by Q4FY26, with benefits expected to start flowing in from early FY27. What are the synergies you see from the merger? The merger unlocks significant synergies that will drive growth, operational efficiencies, and enhanced patient care across the combined network. Integrating our extensive hospital portfolios will allow the new entity to benefit from economies of scale by negotiating better terms with suppliers, reducing costs, and streamlining inventory management that will lower operational expenses and improve margins. What is the capex plan for fiscal 2026, especially in light of the merger-driven expansion? How many more hospitals and beds to come up this fiscal? We plan to add 1,700 beds by FY27, taking the total bed tally in India to over 6,800 through the organic route and will further look for expansion through the inorganic route. Our overall capital allocation for expansion across the domestic market is Rs 1,400 crore, of which we have already spent around Rs 350-400 crore. You have announced a Rs 850-crore investment in Kerala. What is the strategic thinking behind focusing so much on Kerala, which is often seen as a relatively mature market? Kerala is now poised for a significant transformation with a planned investment of Rs 850 crore over the next three years. This expansion will be anchored by two major greenfield projects: Aster Capital Trivandrum, a 454-bed tertiary care facility, and Aster MIMS Kasaragod, a 264-bed multispecialty hospital. In addition, our flagship hospital, Aster Medcity in Kochi, is undergoing a substantial upgrade. By FY27, our total bed capacity in Kerala is expected to reach 3,453, marking a milestone in our journey of delivering quality healthcare and driving sustainable growth. Affordable healthcare remains a chimera for the average citizen. What is Aster doing differently on this front? To balance affordability and sustainability, we centralise complex procedures in larger hospitals, while smaller units focus on primary/secondary care. By FY27, as much as 57% of our planned bed additions will be in tier 2/3 cities, reinforcing our commitment to these regions. Technology is key to bridging gaps, with telemedicine set to grow at 20.7% annually till FY30, reaching $15.1 billion. Our digital health arm is expanding tele-ICU, teleradiology, AI-driven diagnostics, IoT monitoring, and EMR platforms to enhance accessibility, affordability, and quality care nationwide. What are the digital initiatives of the group? Some of our technology-driven, patient-friendly initiatives include the introduction of the Aster Health app that offers appointment bookings, e-pharmacy, and access to digital health records. We have come up with AI-powered diagnostic solutions, including the Carpal Tunnel Syndrome detection tool in collaboration with the Indian Institute of Science. We are also expanding the home healthcare services under Aster@Home, providing in-home consultations, diagnostics, and physiotherapy, catering to India's growing elderly and chronic care populations.

Business Standard

an hour ago

• Business Standard

Sebi bans two from markets for 3 yrs; impounds illegal gains of ₹4.83 cr

Markets regulator Sebi has barred two individuals from the securities markets for three years and impounded illegal gains of over Rs 4.83 crore made by them for orchestrating a fraudulent scheme using out of the money (OTM) stock options to misappropriate funds from investors. Apart from the securities market ban, the regulator also slapped a penalty of Rs 25 lakh each on Shivprasad Pattiya and Alkesh Narware and directed them them to pay the fine within 45 days, Sebi said in the order passed on Friday. Further, Sebi directed Pattiya and Narware to disgorge unlawful gains worth Rs 4.83 crore with an interest of 12 per cent per annum jointly and severally from February 2022. In the final order, Sebi found that the front entities had opened the trading accounts under the instructions of the operator group (Shivprasad Pattiya and Alkesh Narware) and these trading accounts and bank accounts were under the control of the operator group. Sebi observed that the caller group had identified prospective investors (complainants) which had credit balance in their ledger and obtained their credentials in the name of Algo/software trades and the same were also under the control of the Shivprasad Pattiya and Alkesh Narware. The trades executed through the mobile in the accounts of the complainants and the front entities were also under the control of the Pattiya and Narware, Sebi said. "...it is established that the entire fraudulent scheme is attributable solely and squarely to the noticees (operator group) and they were the controlling minds and beneficiaries of the fraudulent arrangement. "The acts of the noticee amounts to manipulative, deceptive device and artifice to defraud while dealing in securities," Sebi's Quasi Judicial Authority N Murugan said in the order. Pattiya and Narware were found to have violated the provisions of PFUTP (Prohibition of Fraudulent and Unfair Trade Practices) rules. The order came after the Securities and Exchange Board of India (Sebi) received alerts on suspicious trades in illiquid 'Out of the Money' stock options with unusual price variations. NSE also got complaints from investors who suffered losses after sharing trading credentials for Algo-based trading via WhatsApp groups. Thereafter, Sebi conducted a probe to look into the role of a group of entities led Shivprasad Pattiya and Alkesh Narware allegedly misused online trading kits, promised guaranteed returns, and executed manipulative trades. The investigation covered the period from January 2021 to February 2022.